Nucleic acid delivery formulations

• US 20040147466A1
• Filed: 03/15/2004
• Published: 07/29/2004
• Est. Priority Date: 01/17/2002
• Status: Abandoned Application

• Current Assignee: MGI Pharma Biologics, Inc.
• Original Assignee: MGI Pharma Biologics, Inc.
• Inventors: Roy, Krishnendu, Wang, Daoing, Hedley, Mary Lynne, Barman, Shikha P.
• Application Number:
  US10/466,289
• Publication Number:
  US 20040147466A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/0041 the non-active part being polymeric

Abstract

The invention is based on the discovery that injectable and nucleic acid-compatible polymeric compositions and formulations can be structurally designed to regulate nucleic acid activity or gene expression in vivo, for example, by controlling the bioavailability of the nucleic acid via modulation of the biodegradability and crosslink density of the network formed by the components of the formulation. The polymeric network encases the nucleic acid, not only controlling the release of the DNA, but also providing protection from degradation. The invention described herein improves upon prior modes of gene delivery, in that gene expression can be regulated by modulation of a polymeric network formed by combination of at least two water-soluble components capable of reacting with one another. The nucleic acid of interest is incorporated into the network to be released in a sustained manner to achieve level and duration of activity or expression needed.

Claims

1. An injectable aqueous formulation, comprising:

a nucleic acid;

a first non-nucleic acid, water-soluble component; and

a second non-nucleic acid, water-soluble component,

wherein the first and second components each include two or more reactive groups, the reactive groups of the first component being reactive with the reactive groups of the second component.

2. The formulation of claim 1, wherein the first and second components react with one another to form a branched or a crosslinked polymeric network.

3. The formulation of claim 1, wherein at least one of the first and second components includes one or more reactive groups selected from the group consisting of succinimidyl, chloroformate, acrylate, amino, alcohol, tetrathiol, epoxide, sulfhydryl, and hydrazidyl groups.

4. The formulation of claim 1, wherein at least one of the first and second components is a functionalized multi-armed poly(alkylene oxide).

5. The formulation of claim 1, wherein one of the first and second components is polyethylene glycol tetraamine.

6. The formulation of claim 1, wherein one of the first and second components is polyethylene glycol tetrasuccinimidyl glutarate.

7. The formulation of claim 1, wherein at least one of the first and second components is a functionalized poly(alkylene oxide) with at least two reactive functional groups.

8. The formulation of claim 1, wherein one of the first and second components is a polyamidoamine having 4 to 8 reactive functional groups.

9. The formulation of claim 1, wherein at least one of the first and second components is a polyethylimine or polylysine derivative.

10. The formulation of claim 1, wherein at least one of the first and second components is a functionalized chitosan, cyclodextrin, or poly(vinyl alcohol) with at least two reactive functional groups.

11. The formulation of claim 1, wherein one or both of the first and second components includes three or more reactive groups, the reactive groups of the first component being reactive with the reactive groups of the second component.

12. The formulation of claim 1, further comprising a third non-nucleic acid, water-soluble component, wherein the third component includes at least one reactive group, the reactive group being reactive with at least one reactive group of the first component, with at least one reactive group of the second component, with at least one reactive group of each of the first and second components, or with at least one reactive group of the product formed by reacting the first and second components.

13. The formulation of claim 1, further comprising methoxy-polyethylene glycol-di-stearoyl-phosphatidylethanolamine (PEG-DSPE).

14. The formulation of claim 1, further comprising an excipient.

15. The formulation of claim 1, wherein the formulation comprises more than one species of nucleic acid.

16. The formulation of claim 1, wherein the nucleic acid is an oligonucleotide.

17. The formulation of claim 1, wherein the nucleic acid encodes a therapeutic protein or a protein that induces an immune response.

18. The formulation of claim 1, wherein the nucleic acid is in a solution, dispersion, or emulsion.

19. The formulation of claim 1, wherein the nucleic acid is encapsulated in a biodegradable polymeric microsphere.

20. The formulation of claim 2, wherein the nucleic acid is released from the branched or crosslinked polymeric network by biodegradation or by simple diffusion.

21. The formulation of claim 1, wherein said formulation forms a hydrogel at a temperature between about 20°

C. and about 40°

C. within about 20 minutes after said formulation is prepared.

22. The formulation of claim 1, wherein the formulation remains injectable for at least fifteen seconds after said formulation is prepared.

23. The formulation of claim 21, wherein the formulation remains injectable for at least fifteen seconds after said formulation is prepared.

24. The formulation of claim 2, wherein the network forms a viscous liquid.

25. The formulation of claim 2, wherein release of the nucleic acid following injection is controlled by the cross-linking density of the network.

26. The formulation of claim 2, wherein expression of the nucleic acid following injection is controlled by the cross-linking density of the network.

27. The formulation of claim 1, wherein the first and second components are biodegradable.

28. The formulation of claim 2, wherein the network is biodegradable.

29. The polymeric network of claim 2, wherein the branched or crosslinked polymeric network comprises linkages selected from the group consisting of ester, carbonate, imino, hydrazone, acetal, orthoester, peptide, amide, urethane, urea, amino, oligonucleotide, and sulfonamidyl bonds.

30. The formulation of claim 27, wherein the first and second components are biodegradable by a hydrolytic or proteolytic mechanism.

31. The formulation of claim 2, wherein the network is partially crosslinked.

32. The formulation of claim 2, wherein the network is fully crosslinked.

33. The formulation of claim 27, wherein the components comprise one or more functional groups selected from the group consisting of sulfhydryl, amine, epoxide, phosphoroamidite, chloroformate, acrylate, carboxylic acid, aldehyde, succinimide ester, succinimide carbonate, maleimide, iodoacetyl, carbohydrate, isocyanate, and isothiocyanate groups.

34. The formulation of claim 1, wherein at least one of the first and second components comprises a biodegradable linkage selected from the group consisting of lactates, caproates, methylene carbonates, glycolates, ester-amides, ester-carbonates, and combinations thereof.

35. The formulation of claim 14, wherein the excipient is selected from the group consisting of neutral, anionic, and cationic lipids.

36. The formulation of claim 14, wherein the excipient is selected from the group consisting of polyethylene glycol, chitosan, hyaluronic acid, chrondoitin sulfate, heparan sulfate, phosphatidyl inositol, glucosamine, polyvinyl alcohol, pluronics, derivatized pluronics, and derivatized polyethylene glycol.

37. The formulation of claim 14, wherein the excipient comprises a permeation enhancer.

38. The formulation of claim 14, wherein the excipient comprises a bioavailability enhancer.

39. The formulation of claim 14, wherein the excipient is a cytokine.

40. The formulation of claim 14, wherein the excipient is a small molecule drug.

41. The formulation of claim 14, wherein the excipient is chemically bound to the crosslinked polymeric network or branched polymer.

42. A method of making a polypeptide, the method comprising applying the formulation of claim 1 to a cell, wherein the nucleic acid codes for expression of the polypeptide.

43. The method of claim 42, wherein the formulation is applied to a cell within an animal.

44. The method of claim 43, wherein the formulation is administered to the animal by injection, extrusion, or spraying.

45. A method of making a polypeptide, the method comprising injecting into an animal the formulation of claim 1, wherein the nucleic acid codes for expression of the polypeptide.

46. The method of claim 45, wherein the formulation is injected in, on, or adjacent to a tumor.

47. The method of claim 45, wherein the formulation is injected intra-joint.

48. The method of claim 45, wherein the formulation is injected into the animal more than once.

49. The method of claim 45 wherein the formulation of claim 1 is premixed before injection.

50. The method of claim 45, wherein the animal is a human.

51. A method of producing a polypeptide, the method comprising:

providing a surface suitable for cell culture;

adding the formulation of claim 1 to the surface; and

placing a cell on the formulation,

wherein the nucleic acid codes for expression of the polypeptide, and wherein the cell produces the polypeptide following the culturing of the cell in vitro.

52. A method of making a nucleic acid-containing microparticle preparation, the method comprising:

introducing the nucleic acid and the first and second non-nucleic acid components of the formulation of claim 1 into an emulsifying bath; and

emulsifying the resulting mixture during at least part of the time that said first and second non-nucleic acid, water-soluble components are reacting with each other, to result in microparticles containing said nucleic acid molecules.

53. The method of claim 52, wherein said stirring is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 500 microns.

54. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 250 microns.

55. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 100 microns.

56. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 50 microns.

57. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 20 microns.

58. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 15 microns.

59. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 10 microns.

60. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 5 microns.

61. The method of claim 52, wherein said emulsifying is sufficiently vigorous so as to result in microparticles having an average diameter of less than about 1 microns.

62. The method of claim 52, wherein said introducing step comprises coextruding said first and second components into an aqueous solution in the emulsifying bath.

63. The formulation of claim 1, wherein said formulation comprises microparticles.

64. A method of making a dried nucleic acid formulation comprising:

(a) preparing a mixture by mixing in an aqueous solution

(i) a nucleic acid,

(ii) a first non-nucleic acid, water-soluble component,

(iii) a second non-nucleic acid, water-soluble component, and

(iv) a third non-nucleic acid, water-soluble component,

wherein the first and second components each include two or more reactive groups, the reactive groups of the first component being reactive with the reactive groups of the second component at a pH greater than 7.0, and

wherein the aqueous solution has a pH and temperature that prevents the first and second components from reacting to form a cross-linked network; and

(b) drying the mixture to thereby create a dried nucleic acid formulation.

65. The method of claim 64, wherein the mixing is performed at a pH less than about 7.0.

66. The method of claim 65, wherein the mixing is performed at a pH less than about 6.0.

67. The method of claim 66, wherein the mixing is performed at a pH of about 5.5.

68. The method of claim 64, wherein the mixing is performed at or below about 4°

C.

69. The method of claim 64, wherein the mixture is lyophilized.

70. The method of claim 64, wherein the first non-nucleic acid, water-soluble component is polyethylene glycol amine.

71. The method of claim 64, wherein the second non-nucleic acid, water-soluble component is polyethylene glycol succinimidyl glutarate.

72. The method of claim 64, wherein the third non-nucleic acid, water-soluble component is methoxy-polyethylene glycol-di-stearoyl-phosphatidylethanolamine (PEG-DSPE).

73. A method of preparing a nucleic acid-containing formulation, the method comprising adding a buffer having a pH greater than 7.0 to the dried nucleic acid formulation of claim 64, wherein the addition of the buffer results in the formation of a crosslinked network between the first and second components.

74. The method of claim 73, wherein the buffer is a phosphate buffer and has a pH of about 7.5.

75. The method of claim 73, wherein the adding step is performed at or above 20°

C.

76. The method of claim 75, wherein the adding step is performed at or above 37°

C.

77. The method of claim 64, wherein the third component includes at least one reactive group that is reactive at a pH greater than 7.0 with at least one reactive group of the first component, with at least one reactive group of the second component, with at least one reactive group of each of the first and second components, or with at least one reactive group of the product formed by reacting the first and second components.

78. A dried formulation comprising:

(a) a nucleic acid;

(b) a first non-nucleic acid, water-soluble component;

(c) a second non-nucleic acid, water-soluble component; and

(d) a third non-nucleic acid, water-soluble component,

wherein the first and second components each include two or more reactive groups, the reactive groups of the first component being reactive with the reactive groups of the second component,

wherein the first and second components are in an unreacted state, and wherein the nucleic acid and the three components are not in solution.

79. The formulation of claim 78, wherein the formulation is lyophilized.

80. The formulation of claim 78, wherein the first non-nucleic acid, water-soluble component is polyethylene glycol amine.

81. The formulation of claim 78, wherein the second non-nucleic acid, water-soluble component is polyethylene glycol succinimidyl glutarate.

82. The formulation of claim 78, wherein the third non-nucleic acid, water-soluble component is methoxy-polyethylene glycol-di-stearoyl-phosphatidylethanolamine (PEG-DSPE).

83. A kit comprising:

the formulation of claim 78;

and

a buffer having a pH of at least 7.0.

84. A method of administering a nucleic acid to an individual the method comprising:

preparing a mixture by adding a buffer having a pH of at least 7.0 to the formulation of claim 78;

incubating the mixture to permit the formation of a crosslinked network; and

administering the mixture to the individual.

85. The formulation of claim 78, wherein the third component includes at least one reactive group that is reactive at a pH greater than 7.0 with at least one reactive group of the first component, with at least one reactive group of the second component, with at least one reactive group of each of the first and second components, or with at least one reactive group of the product formed by reacting the first and second components.

86. A method of delivering a particle to an individual, the method comprising:

administering to the individual a formulation comprising said particle;

a first, non-nucleic acid, water soluble component; and

a second, non-nucleic acid, water soluble component, wherein the first and second components each include two or more reactive groups, the reactive groups of the first component being reactive with the reactive groups of the second component.

87. The method of claim 86, wherein the particle is a virus or viral particle.

88. The method of claim 86, wherein the particle is an adenovirus or adenoviral particle.